Neutralization of tumor necrosis factor-alpha or interleukin-1 prevents obliterative airway disease in HLA-A2 transgenic murine tracheal allografts.

Smith, Carter; Jaramillo, Andrés; Lu, Kim C.; Kaleem, Zahid; Patterson, G.A.; Mohanakumar, T.

doi:10.1016/s1053-2498(00)00306-5

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, lung transplantation remains the only therapeutic option for patients with BO. The potential involvement of inflammatory cytokines, 6 chemokines, 7 growth factors, 8 extracellular matrices, 9 angiogenic factors, 10 and epithelial mesenchymal transition 11 in the development of BO has been reported in research based on several animal experiments, but questions remain in terms of the reproducibility of human BO in which the primary obstructive lesions are exclusively limited to the area of the membranous bronchioli.…”

Section: Introductionmentioning

confidence: 99%

Histopathological bronchial reconstruction of human bronchiolitis obliterans

Sugino

Hebisawa

Uekusa³

et al. 2011

Pathology International

View full text Add to dashboard Cite

To clarify the morphological mechanisms of airway obliteration in bronchiolitis obliterans (BO) associated with various causes, we conducted a retrospective study of 9 patients with a histological diagnosis of BO. The morphological characteristics were analyzed by histopathological bronchial reconstruction. BO was classified into two major morphologic subtypes: constrictive BO (CoB) and cellular/destructive BO (CDB). CoB is characterized by concentric narrowing of the airway lumen due to submucosal fibrosis. In contrast, in CDB the narrowing of the airway lumen is due to intraluminal, mural, and peribronchiolar infiltration of inflammatory cells as well as proliferation of granulation tissue. The histopathological diagnosis was CoB in 6 patients and CDB in 3 patients. Macroscopic bronchial reconstruction in CoB demonstrated that the beginnings of bronchial obliterations were in the 4th to 7th branches, numbering from each segmental bronchus and the lesions were distributed intermittently. Histopathologically, the localization of obliteration was mainly from small bronchi to membranous bronchioli with intermittent airway luminal obliteration in CoB, whereas the primary lesions in CDB revealed more continuous obliteration of the bronchiolar lumen than observed in CoB. In conclusion, this bronchial reconstruction study demonstrated marked morphological differences in the mechanisms of airway obliteration between two major morphologic subtypes of BO.

show abstract

Section: Introductionmentioning

confidence: 99%

Histopathological bronchial reconstruction of human bronchiolitis obliterans

Sugino

Hebisawa

Uekusa³

et al. 2011

Pathology International

View full text Add to dashboard Cite

show abstract

“…A fibroproliferative phase develops later in the airways in which macrophages and myofibroblasts predominate. Cytokines (TNF-␣, IL-1␤, IL-6, IFN-␥, and IL-2) have been implicated in the pathogenesis of OB/BOS (71)(72)(73)(74)(75)(76). The regulatory cytokines IL-12 and IL-10 also likely play a key role in this process, but have not been studied in detail.…”

Section: Immunology Of the Host Response: Acute And Chronic Rejectionmentioning

confidence: 99%

Lung Transplantation

Wilkes

Egan

Reynolds

2005

Am J Respir Crit Care Med

View full text Add to dashboard Cite

Lung transplantation is the only definitive therapy for many forms of end-stage lung diseases. However, the success of lung transplantation is limited by many factors: (1) Too few lungs available for transplantation due to limited donors or injury to the donor lung; (2) current methods of preservation of excised lungs do not allow extended periods of time between procurement and implantation; (3) acute graft failure is more common with lungs than other solid organs, thus contributing to poorer short-term survival after lung transplant compared with that for recipients of other organs; (4) lung transplant recipients are particularly vulnerable to pulmonary infections; and (5) chronic allograft dysfunction, manifest by bronchiolitis obliterans syndrome, is frequent and limits long-term survival. Scientific advances may provide significant improvements in the outcome of lung transplantation. The National Heart, Lung, and Blood Institute convened a working group of investigators on June 14-15, 2004, in Bethesda, Maryland, to identify opportunities for scientific advancement in lung transplantation, including basic and clinical research. This workshop provides a framework to identify critical issues related to clinical lung transplantation, and to delineate important areas for productive scientific investigation.

show abstract

Maintenance Azithromycin Therapy for Bronchiolitis Obliterans Syndrome

Gerhardt

McDyer²,

Girgis³

et al. 2003

Am J Respir Crit Care Med

292

183

View full text Add to dashboard Cite

Bronchiolitis obliterans syndrome remains the leading cause of morbidity and mortality in the pulmonary transplant population. Previous studies show that macrolide antibiotics may be efficacious in the treatment of panbronchiolitis and cystic fibrosis. In the latter, azithromycin decreases the number of respiratory exacerbations, improves FEV1, and improves quality of life. We hypothesized that oral azithromycin therapy may improve lung function in patients with bronchiolitis obliterans syndrome. To test this hypothesis, we conducted an open-label pilot trial using maintenance azithromycin therapy in six lung transplant recipients (250 mg orally three times per week for a mean of 13.7 weeks). In this study, five of these six individuals demonstrated significant improvement in pulmonary function, as assessed by FEV1, as compared with their baseline values at the start of azithromycin therapy. The mean increase in the percentage of predicted FEV1 values in these individuals was 17.1% (p

show abstract

Neutralization of tumor necrosis factor-alpha or interleukin-1 prevents obliterative airway disease in HLA-A2 transgenic murine tracheal allografts.

Cited by 4 publications

References 0 publications

Histopathological bronchial reconstruction of human bronchiolitis obliterans

Histopathological bronchial reconstruction of human bronchiolitis obliterans

Lung Transplantation

Maintenance Azithromycin Therapy for Bronchiolitis Obliterans Syndrome

Contact Info

Product

Resources

About